ImmuCell (NASDAQ:ICCC) Share Price Passes Above 200 Day Moving Average - Should You Sell?

Key Points

• ImmuCell shares have crossed above their 200-day moving average, trading at $6.13, up from a 200-day average of $5.89.
• The biotechnology company reported a quarterly EPS of $0.06 with a revenue of $6.45 million, reflecting a net margin of 6.23%.
• Institutional investors currently own 13.47% of ImmuCell stock, with notable increases in holdings by Northern Trust Corp and Geode Capital Management.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.89 and traded as high as $6.42. ImmuCell shares last traded at $6.13, with a volume of 13,036 shares trading hands.

ImmuCell Trading Down 0.5%

The firm has a market capitalization of $55.48 million, a P/E ratio of 32.26 and a beta of 0.29. The company has a quick ratio of 1.99, a current ratio of 3.85 and a debt-to-equity ratio of 0.28. The business has a 50-day moving average price of $6.40 and a 200-day moving average price of $5.89.

ImmuCell (NASDAQ:ICCC - Get Free Report) last issued its earnings results on Thursday, August 14th. The biotechnology company reported $0.06 EPS for the quarter. The company had revenue of $6.45 million for the quarter. ImmuCell had a net margin of 6.23% and a return on equity of 6.25%.

Hedge Funds Weigh In On ImmuCell

Several large investors have recently bought and sold shares of ICCC. Northern Trust Corp boosted its stake in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 14,982 shares during the last quarter. Citadel Advisors LLC bought a new stake in ImmuCell in the fourth quarter valued at about $149,000. Finally, Geode Capital Management LLC increased its holdings in ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after purchasing an additional 2,907 shares during the last quarter. 13.47% of the stock is currently owned by institutional investors and hedge funds.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.